Biotech Business

Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors

Published in Clinical Oncology Week, December 10th, 2007

Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for autoimmune disease and cancer, announced the retirement of Steven C. Wheelwright, PhD from its Board of Directors and the addition of Robert Gay, PhD.

Dr. Wheelwright served as a Director at Merrimack since May 2006. He was recently named the President of Brigham Young University Hawaii and is stepping down due to his relocation. Most recently, Dr. Wheelwright served as a Baker Foundation Professor and Chairman of HBS Publishing at Harvard Business School, while serving on numerous boards including Merrimack.

"Steve...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2007-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry